Deciphera Pharmaceuticals Q3 EPS $(0.58) Beats $(0.61) Estimate, Sales $43.31M Beat $39.35M Estimate
Portfolio Pulse from Benzinga Newsdesk
Deciphera Pharmaceuticals reported Q3 earnings per share of $(0.58), beating the analyst consensus estimate of $(0.61) by 4.92%. This is a 5.45% decrease from the same period last year. The company also reported quarterly sales of $43.31 million, beating the analyst consensus estimate of $39.35 million by 10.07%. This is a 20.40% increase from the same period last year.
October 30, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Deciphera Pharmaceuticals reported better than expected Q3 earnings and sales, which could positively impact the stock in the short term.
Deciphera Pharmaceuticals reported Q3 earnings and sales that beat analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100